Intellia Therapeutics had its Relative Strength (RS) Rating upgraded from 62 to 90 Friday.
Here Are 3 Keys For Successful Stock Investing
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or higher RS Rating at the beginning of a new price run.
Intellia Therapeutics has climbed more than 5% past a 14.61 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Intellia Therapeutics reported 0% EPS growth in the latest quarterly report, while sales growth came in at 105%.
The company holds the No. 136 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
